Lactam inhibitors of 11-β-hydroxysteroid dehydrogenase 1

US8680281B2 · kind B2 · utility

Assignees

• Vitae Pharmaceuticals, LLC · US
• Boehringer Ingelheim International GmbH · DE

Inventors

• David A. Claremon · Audubon, US
• Linghang Zhuang · Doylestown, US
• Yuanjie Ye · Ambler, US
• Suresh B. Singh · Kendall Park, US
• Colin M. Tice · Ambler, US
• Zhenrong Xu · Forest Park, US
• Robert D. Simpson · Wilmington, US

Key dates

• Filing date: Jan 7, 2009
• Grant date: Mar 25, 2014
• Expiry date: Nov 13, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to novel compounds of the Formula (I), (I*), (Ia), (Ib), (Ic), (Id), (Ie), (If), (If*), (Ig), (Ih), (Ij), (Ik), (ll1-3 ), (Im1-3), (In1-3), (lo1-2), (Ip1-9), (Iq1-9), (Ir1-9) and (Is1-3) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell. (I)